TROP2 ADC sac-TMT extends survival in advanced endometrial cancer, offering a potential new treatment option after chemotherapy and immunotherapy failure in a late-stage clinical trial.
Eris Lifesciences targets semaglutide market expansion to Rs 80-90 crore monthly by next year, driven by rising demand for diabetes therapies.
GSK and Hansoh's Ris-Rez shows promise in osteosarcoma treatment, reducing progression risk in a Phase III trial and highlighting unmet needs after relapse.
Haryana ends OPD queue hardship with UPI payments and home registration, making public hospital visits faster, simpler and more convenient.
Biocon’s Yesintek gains market entry into nine high-growth markets, expanding its global biosimilar reach through a settlement with Janssen Sciences Ireland.
AIG Hospitals and Boston Scientific are expanding specialist training to support access to advanced gastrointestinal procedures beyond major Indian cities.
A KGMU report highlights gaps in breast cancer screening follow-up in Uttar Pradesh, raising concerns about timely diagnosis and access to care.
India has come a long way in the management of cardiovascular disease. With advances in diagnostics, interventional cardiology and cardiac surgery, patients with complex heart conditions have more options than ever before. However, access to newer su
If you stand at a chemist counter in Delhi for half an hour, you'll notice something. A good share of what people ask for is skin related: a cream for a rash that won't go
Roche’s next-generation drug divarasib cuts lung cancer death risk by 44%, offering longer survival and improved treatment tolerability.